Perlecan domain 1 recombinant proteoglycan augments BMP-2 activity and osteogenesis

BMC Biotechnology

Volumn 12, Issue , 2012, Pages

  DeCarlo, Arthur A ^a   Belousova, Maria ^a   Ellis, April L ^a   Petersen, Donald ^a   Grenett, Hernan ^a   Hardigan, Patrick ^b   O'Grady, Robert ^c   Lord, Megan ^c   Whitelock, John M ^c  

^a Agenta Biotechnologies Inc   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

BMP 2; Bone graft; Chondroitin sulfate; Heparan sulfate; Implant; Osteoblast; Osteogenesis; Perlecan; Proteoglycan; TCP

Indexed keywords

BMP-2; BONE GRAFT; CHONDROITIN SULFATES; HEPARAN SULFATES; OSTEOGENESIS; PERLECAN; PROTEOGLYCANS; TCP;

BONE; CELLS; CYTOLOGY; DNA; DRUG DOSAGE; IMPLANTS (SURGICAL); OSTEOBLASTS; POLYMERS; RECOMBINANT PROTEINS; SULFUR COMPOUNDS; TRANSMISSION CONTROL PROTOCOL;

SCAFFOLDS (BIOLOGY);

BONE MORPHOGENETIC PROTEIN 2; CALCIUM PHOSPHATE; CHONDROITIN SULFATE; COLLAGEN SPONGE; GLYCOSAMINOGLYCAN; GROWTH FACTOR; HEPARAN SULFATE; PERLECAN; POLYMER; PRODRUG; PROTEOGLYCAN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT HUMAN PERLECAN DOMAIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE DEVELOPMENT; BONE GRAFT; BONE MASS; CELL FUNCTION; CELL STRAIN HEK293; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAXILLA; NONHUMAN; PROTEIN EXPRESSION; RAT;

3T3 CELLS; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; HEK293 CELLS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MALE; MICE; OSTEOBLASTS; OSTEOGENESIS; PROTEIN STRUCTURE, TERTIARY; PROTEOGLYCANS; RATS; RATS, INBRED LEW;

RATTUS;

EID: 84865967877     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-12-60     Document Type: Article

References (41)

1. Dombrowski C, Song SJ, Chuan P, Lim X, Susanto E, Sawyer AA, Woodruff MA, Hutmacher DW, Nurcombe V, Cool SM. Heparan sulfate mediates the proliferation and differentiation of rat mesenchymal stem cells. Stem Cells Dev 2009, 18(4):661-670. 10.1089/scd.2008.0157, 18690792.
2. Allen BL, Rapraeger AC. Spatial and temporal expression of heparan sulfate in mouse development regulates FGF and FGF receptor assembly. J Cell Biol 2003, 163(3):637-648. 10.1083/jcb.200307053, 2173664, 14610064.
3. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, Mohammadi M. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 2000, 6(3):743-750. 10.1016/S1097-2765(00)00073-3, 11030354.
4. Ornitz DM. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 2000, 22(2):108-112. 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M, 10655030.
5. Wu ZL, Zhang L, Yabe T, Kuberan B, Beeler DL, Love A, Rosenberg RD. The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex. J Biol Chem 2003, 278(19):17121-17129. 10.1074/jbc.M212590200, 12604602.
6. Muthusamy A, Cooper CR, Gomes RR. Soluble Perlecan Domain I Enhances Vascular Endothelial Growth Factor-165 Activity and Receptor Phosphorylation in Human Bone Marrow Endothelial Cells. BMC Biochem 2010, 11(1):43. 10.1186/1471-2091-11-43, 2987766, 21047416.
7. Chuang CY, Lord MS, Melrose J, Rees MD, Knox SM, Freeman C, Iozzo RV, Whitelock JM. Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan. Biochemistry 2010, 49(26):5524-5532. 10.1021/bi1005199, 2900151, 20507176.
8. DeCarlo AA, Whitelock JM. The role of heparan sulfate and perlecan in bone-regenerative procedures. J Dent Res 2006, 85(2):122-132. 10.1177/154405910608500203, 16434729.
9. Cool S, Nurcombe V. Heparan sulfate regulation of progenitor cell fate. J Cell Biochem 2006, 99(4):1040-1051. 10.1002/jcb.20936, 16767693.
10. Lamoureux F. Baud'huin M, Duplomb L, Heymann D, Rédini F: Proteoglycans: key partners in bone cell biology. Bioessays 2007, 29(8):758-771. 10.1002/bies.20612, 17621645.
11. Woodruff MA, Rath SN, Susanto E, Haupt LM, Hutmacher DW, Nurcombe V, Cool SM. Sustained release and osteogenic potential of heparan sulfate-doped fibrin glue scaffolds within a rat cranial model. J Mol Histol 2007, 38(5):425-433. 10.1007/s10735-007-9137-y, 17849224.
12. Yang W, Gomes RR, Brown AJ, Burdett AR, Alicknavitch M, Farach-Carson MC, Carson DD. Chondrogenic differentiation on perlecan domain I, collagen II, and bone morphogenetic protein-2-based matrices. Tissue Eng 2006, 12(7):2009-2024. 10.1089/ten.2006.12.2009, 1774589, 16889529.
13. Jha AK, Yang W, Kirn-Safran CB, Farach-Carson MC, Jia X. Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release. Biomaterials 2009, 30(36):6964-6975. 10.1016/j.biomaterials.2009.09.009, 2783995, 19775743.
14. Takada T. Sulfated Polysaccharides Enhance the Biological Activities of Bone Morphogenetic Proteins. J Biol Chem 2003, 278(44):43229-43235. 10.1074/jbc.M300937200, 12912996.
15. Irie A, Habuchi H, Kimata K, Sanai Y. Heparan sulfate is required for bone morphogenetic protein-7 signaling. Biochem Biophys Res Commun 2003, 308(4):858-865. 10.1016/S0006-291X(03)01500-6, 12927798.
16. Ruppert R, Hoffmann E, Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 1996, 237(1):295-302. 10.1111/j.1432-1033.1996.0295n.x, 8620887.
17. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 1996, 271:10079-10086. 10.1074/jbc.271.17.10079, 8626565.
18. Yang WD, Gomes RR. Alicknavitch M, Farach-Carson MC, Carson DD: Perlecan domain I promotes fibroblast growth factor 2 delivery in collagen I fibril scaffolds. Tissue Eng 2005, 11(1-2):76-89. 1635240, 15738663.
19. Casper CL, Yang W, Farach-Carson MC, Rabolt JF. Coating electrospun collagen and gelatin fibers with perlecan domain I for increased growth factor binding. Biomacromolecules 2007, 8(4):1116-1123. 10.1021/bm061003s, 17326680.
20. Deepa SS. Specific Molecular Interactions of Oversulfated Chondroitin Sulfate E with Various Heparin-binding Growth Factors. Implication as a physiological binding partner in the brain and other tissues. J Biol Chem 2002, 277(46):43707-43716.
21. Li F. Shetty AK. Sugahara K: Neuritogenic activity of chondroitin/dermatan sulfate hybrid chains of embryonic pig brain and their mimicry from shark liver. Involvement of the pleiotrophin and hepatocyte growth factor signaling pathways. J Biol Chem 2007, 282(5):2956-2966.
22. Miyazaki T, Miyauchi S, Tawada A, Anada T, Matsuzaka S, Suzuki O. Oversulfated chondroitin sulfate-E binds to BMP-4 and enhances osteoblast differentiation. J Cell Physiol 2008, 217(3):769-777. 10.1002/jcp.21557, 18720384.
23. Yasunori Shintani STYAHKYLSYOTOSH. Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling. EMBO J 2006, 25(13):3045. 10.1038/sj.emboj.7601188, 1500974, 16763549.
24. Whitelock JM, Iozzo RV. Heparan sulfate: a complex polymer charged with biological activity. Chem Rev 2005, 105(7):2745-2764. 10.1021/cr010213m, 16011323.
25. Ellis AL, Pan W, Yang G, Jones K, Chuang C, Whitelock JM, DeCarlo AA. Similarity of recombinant human perlecan domain 1 by alternative expression systems bioactive heterogenous recombinant human perlecan D1. BMC Biotechnol 2010, 10(66):10-66. 2841091, 20146813.
26. Qiu X, Schroeder P, Bridon D. Identification and characterization of a C(K/R)TC motif as a common epitope present in all subtypes of hepatitis B surface antigen. J Immunol 1996, 156:3350-3356.
27. Khan S, Rodriguez E, Patel R, Gor J, Mulloy B, Perkins SJ. The Solution Structure of Heparan Sulfate Differs from That of Heparin: Implications for Function. J Biol Chem 2011, 286(28):24842-24854. 10.1074/jbc.M111.226027, 3137059, 21576246.
28. Rudd TR, Uniewicz KA, Ori A, Guimond SE, Skidmore MA, Gaudesi D, Xu R, Turnbull JE, Guerrini M, Torri G, et al. Comparable stabilisation, structural changes and activities can be induced in FGF by a variety of HS and non-GAG analogues: implications for sequence-activity relationships. Org Biomol Chem 2010, 8(23):5390. 10.1039/c0ob00246a, 20865198.
29. Abramsson A, Kurup S, Busse M, Yamada S, Lindblom P, Schallmeiner E, Stenzel D, Sauvaget D, Ledin J, Ringvall M, et al. Defective N-sulfation of heparan sulfate proteoglycans limits PDGF-BB binding and pericyte recruitment in vascular development. Genes Dev 2007, 21(3):316-331. 10.1101/gad.398207, 1785125, 17289920.
30. Robinson CJ, Mulloy B, Gallagher JT, Stringer SE. VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J Biol Chem 2006, 281(3):1731-1740.
31. van den Born J, Salmivirta K, Henttinen T, Ostman N, Ishimaru T, Miyaura S, Yoshida K, Salmivirta M. Novel heparan sulfate structures revealed by monoclonal antibodies. J Biol Chem 2005, 280(21):20516-20523. 10.1074/jbc.M502065200, 15778504.
32. David G, Bai XM, Van der Schueren B, Cassiman JJ, Van den Berghe H. Developmental changes in heparan sulfate expression: in situ detection with mAbs. J Cell Biol 1992, 119(4):961-975. 10.1083/jcb.119.4.961, 2289686, 1385449.
33. Deepa SS, Yamada S, Fukui S, Sugahara K. Structural determination of novel sulfated octasaccharides isolated from chondroitin sulfate of shark cartilage and their application for characterizing monoclonal antibody epitopes. Glycobiology 2007, 17(6):631-645. 10.1093/glycob/cwm021, 17317718.
34. Ito Y, Hikino M, Yajima Y, Mikami T, Sirko S, von Holst A, Faissner A, Fukui S, Sugahara K. Structural characterization of the epitopes of the monoclonal antibodies 473HD, CS-56, and MO-225 specific for chondroitin sulfate D-type using the oligosaccharide library. Glycobiology 2005, 15(6):593-603.
35. Gandhi NS, Mancera RL. Prediction of heparin binding sites in bone morphogenetic proteins (BMPs). Biochimica Et Biophysica Acta 2012, : .
36. Kuboki Y, Takita H, Kobayashi D, Tsuruga E, Inoue M, Murata M, Nagai N, Dohi Y, Ohgushi H. BMP-induced osteogenesis on the surface of hydroxyapatite with geometrically feasible and nonfeasible structures: topology of osteogenesis. J Biomed Mater Res A 1998, 39(2):190-199.
37. Gao T, Lindholm TS, Marttinen A, Urist MR. Composites of bone morphogenetic protein (BMP) and type IV collagen, coral-derived coral hydroxyapatite, and tricalcium phosphate ceramics. Int Orthop 1996, 20(5):321-325. 10.1007/s002640050086, 8930726.
38. Urist MR, Nilsson O, Rasmussen J, Hirota W, Lovell T, Schmalzreid T, Finerman GA. Bone regeneration under the influence of a bone morphogenetic protein (BMP) beta tricalcium phosphate (TCP) composite in skull trephine defects in dogs. Clin Orthop Relat Res 1987, 214:295-304.
39. Urist MR, Lietze A, Dawson E. Beta-tricalcium phosphate delivery system for bone morphogenetic protein. Clin Orthop Relat Res 1984, 187:277-280.
40. Knox S, Merry C, Stringer S, Melrose J, Whitelock J. Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors. J Biol Chem 2002, 277(17):14657-14565.
41. Eyckmans J, Roberts SJ, Schrooten J, Luyten FP. A clinically relevant model of osteoinduction: a process requiring calcium phosphate and BMP/Wnt signalling. J Cell Mol Med 2010, 14(6B):1845-1856.